{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:59:37Z","timestamp":1769047177728,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1053\/j.seminhematol.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T02:14:27Z","timestamp":1705889667000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Looking to achieve cure the first time around for DLBCL patients who are older and\/or with co-morbidities"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-9841","authenticated-orcid":false,"given":"Elizabeth A.","family":"Brem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.008_bib0001","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0002","unstructured":"Cancer Stat Facts: NHL - Diffuse large b cell lymphoma. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed 25 August 2023."},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0003","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V130.Suppl_1.861.861","article-title":"Enrollment of older adults in clinical trials evaluating patients with hematologic malignancies - the Food and Drug Administration (FDA) Experience","volume":"130","author":"Kanapuru","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.01.008_bib0004","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.01.008_bib0005","first-page":"2566","article-title":"How I treat older patients with DLBCL in the frontline setting","volume":"141","author":"Lugtenburg","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.008_bib0006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11899-019-00519-7","article-title":"Considerations for the treatment of diffuse large B cell lymphoma in the elderly","volume":"14","author":"Kahn","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.008_bib0007","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3324\/haematol.2011.057240","article-title":"Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup","volume":"97","author":"Thunberg","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.008_bib0008","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.clml.2021.06.015","article-title":"Diffuse large B cell lymphoma in patients 80 years and older: worse survival after treatment without increased relapse rates","volume":"21","author":"Keenan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.01.008_bib0009","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.008_bib0010","article-title":"Factors relating to the favorable outcome in reduced-Dose-R-CHOP therapy for elderly DLBCL patients","volume":"132","author":"Ono","year":"2018","journal-title":"ASH Annu Meet"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.01.008_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.008_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jgo.2019.08.005","article-title":"Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of geriatric oncology review paper","volume":"11","author":"DuMontier","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0013","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0014","unstructured":"Merli M, Luminari S, Tucci A et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. 2021. 39(11):1214-1222."},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.008_bib0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jgo.2021.10.003","volume":"13","author":"Brem","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.008_bib0016","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1182\/blood-2022-162870","article-title":"A phase 2, open-label study of Loncastuximab Tesirine in combination with rituximab (Lonca-R) in previously untreated unfit\/frail patients with diffuse large B-Cell lymphoma (DLBCL) (LOTIS-9)","volume":"140","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0017","unstructured":"Press Release Details. ADC therapeutics announces plan to discontinue the phase 2 LOTIS-9 clinical trial of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) and rituximab in unfit or frail previously untreated DLBCL patients. https:\/\/ir.adctherapeutics.com\/press-releases\/press-release-details\/2023\/ADC-Therapeutics-Announces-Plan-to-Discontinue-the-Phase-2-LOTIS-9-Clinical-Trial-of-ZYNLONTA-loncastuximab-tesirine-lpyl-and-Rituximab-in-Unfit-or-Frail-Previously-Untreated-DLBCL-Patients\/default.aspx. Accessed September 4, 2023."},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2024.01.008_bib0018","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1200\/jco.2015.33.15_suppl.8571","article-title":"Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial","volume":"33","author":"Owens","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.01.008_bib0019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.008_bib0020","first-page":"1285","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Chin Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0022","doi-asserted-by":"crossref","unstructured":"Hu B, Reagan PM, Sehn LH et al. Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study. 2023;41(16_suppl):7518-7518.","DOI":"10.1200\/JCO.2023.41.16_suppl.7518"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.01.008_bib0023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428194.2011.600486","article-title":"Rituximab plus 70 % cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older","volume":"53","author":"Meguro","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0024","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma\u202f: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.008_bib0025","first-page":"1203","article-title":"Subcutaneous rituximab-MiniCHOP compared with subcutaneous rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J Chin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.01.008_bib0026","first-page":"1193","article-title":"Improving survival and predicting toxicity in older patients with DLBCL: a delicate balance","volume":"39","author":"Smith","year":"2021","journal-title":"J Chin Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0027","doi-asserted-by":"crossref","unstructured":"Jerkeman M, Lepp\u00e4 S, Hamfjord J et al. Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP. EHA Library. Presented 08-June-2023. Abstract S227.","DOI":"10.1097\/01.HS9.0000967820.91359.ec"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.01.008_bib0028","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/10428194.2011.621565","volume":"54","author":"Merli","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.01.008_bib0029","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/bloodadvances.2023009839","article-title":"A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma","volume":"7","author":"Arcari","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.01.008_bib0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V114.22.408.408","article-title":"R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines","volume":"114","author":"Moccia","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.01.008_bib0031","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De Novo Treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0032","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.01.008_bib0033","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2024.01.008_bib0034","doi-asserted-by":"crossref","unstructured":"Tucci A, Martelli M, Rigacci L et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymph. 215;56(4):921-926.","DOI":"10.3109\/10428194.2014.953142"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.01.008_bib0035","first-page":"1927","article-title":"Rituximab (Anti-CD20 Monoclonal Antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.01.008_bib0036","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood.2022019173","article-title":"Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study","volume":"142","author":"Gini","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.008_bib0037","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.01.008_bib0038","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2023-177588","article-title":"Mosunetuzumab and polatuzumab vedotin demonstrates preliminary efficacy in elderly unfit\/frail patients with previously untreated diffuse large B-cell lymphoma","volume":"142","author":"Olszewski","year":"2023","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:28Z","timestamp":1758522508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0037196324000088"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Looking to achieve cure the first time around for DLBCL patients who are older and\/or with co-morbidities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}